RxDoctor Payments Data

Jane McDonald, MD

Internal Medicine · Grand Island, NENPI 1760421283

Payments from drug & device makers

$1,743in general payments, 2019–2025

Across 105 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$167
  • Lilly USA, LLC$121
  • Pfizer$102
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • AstraZeneca$84
  • Johnson & Johnson$75
  • plus $1K from 36 others

What the payments were for

  • Food & beverage$1,73099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,743 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$187,768
Medicare patients
470
Services billed
5,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$88,791
XareltoRivaroxaban78$70,372
OzempicSemaglutide60$57,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$42,489
Breo ElliptaFluticasone/Vilanterol47$21,316
MyrbetriqMirabegron47$19,963
TrulicityDulaglutide12$19,365
JanumetSitagliptin Phos/Metformin Hcl21$17,814
FarxigaDapagliflozin Propanediol23$17,787
MounjaroTirzepatide18$16,755
JanuviaSitagliptin Phosphate14$16,608
InvokanaCanagliflozin13$14,947
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$11,918
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$8,937
Spiriva RespimatTiotropium Bromide14$8,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$88,791105 claims
Johnson & JohnsonXarelto, Invokana$75$85,31991 claims
GSKTrelegy Ellipta, Breo Ellipta$25$63,80591 claims
Novo NordiskOzempic$43$57,80660 claims
Lilly USA, LLCTrulicity, Mounjaro$121$36,12030 claims
MerckJanumet, Januvia$13$34,42235 claims
AstraZenecaFarxiga, Symbicort$84$22,01641 claims
Astellas Pharma US IncMyrbetriq$36$19,96347 claims
Boehringer IngelheimSpiriva Respimat$32$8,28414 claims
AbbVieSynthroid$30$5,33466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →